Chemokine expression in renal ischemia/reperfusion injury is most profound during the reparative phase

被引:73
作者
Stroo, Ingrid [1 ]
Stokman, Geurt [1 ]
Teske, Gwen J. D. [1 ]
Raven, Anje [1 ]
Butter, Loes M. [1 ]
Florquin, Sandrine [1 ]
Leemans, Jaklien C. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
关键词
chemokine; I/R; kidney; microarray; ISCHEMIA-REPERFUSION INJURY; MRL/LPR MICE; LUPUS NEPHRITIS; CXC CHEMOKINES; CHEMOATTRACTANT; RECEPTORS; DISEASE; KIDNEY; PROGRESSION; NEUTROPHIL;
D O I
10.1093/intimm/dxq025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chemokines are important players in the migration of leukocytes to sites of injury and are also involved in angiogenesis, development and wound healing. In this study, we performed microarray analyses to identify chemokines that play a role during the inflammatory and repair phase after renal ischemia/reperfusion (I/R) injury and investigated the temporal relationship between chemokine expression, leukocyte accumulation and renal damage/repair. C57BI/6 mice were subjected to unilateral ischemia for 45 min and sacrificed 3 h, 1 day and 7 days after reperfusion. From ischemic and contralateral kidney, RNA was isolated and hybridized to a microarray. Microarray results were validated with quantitative real-time reverse transcription-PCR (QRT-PCR) on RNA from an independent experiment. (Immuno)histochemical analyses were performed to determine renal damage/repair and influx of leukocytes. Twenty out of 114 genes were up-regulated at one or more reperfusion periods. All these genes were up-regulated 7 days after I/R. Up-regulated genes included CC chemokines MCP-1 and TARC, CXC chemokines KC and MIP-2 alpha, chemokine receptors Ccr1 and Cx3cr1 and related genes like matrix metalloproteinases. Microarray data of 1 and 7 days were confirmed for 17 up-regulated genes by ORT-PCR. (Immuno)histochemical analysis showed that the inflammatory and repair phase after renal I/R injury take place after, respectively, 1 and 7 days. Interestingly, chemokine expression was highest during the repair phase. In addition, expression profiles showed a biphasic expression of all up-regulated CXC chemokines coinciding with the early inflammatory and late repair phase. In conclusion, we propose that temporal expression of chemokines is a crucial factor in the regulation of renal I/R injury and repair.
引用
收藏
页码:433 / 442
页数:10
相关论文
共 50 条
[1]  
Agrawal M, 2000, AM FAM PHYSICIAN, V61, P2077
[2]   Chemokines and chemokine receptors are involved in the resolution or progression of renal disease [J].
Anders, HJ ;
Vielhauer, V ;
Schlöndorff, D .
KIDNEY INTERNATIONAL, 2003, 63 (02) :401-415
[3]   Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes [J].
Ascon, Miguel ;
Ascon, Dolores B. ;
Liu, Manchang ;
Cheadle, Chris ;
Sarkar, Chaitali ;
Racusen, Lorraine ;
Hassoun, Heitham T. ;
Rabb, Hamid .
KIDNEY INTERNATIONAL, 2009, 75 (05) :526-535
[4]   ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets [J].
Bizzarri, Cinzia ;
Beccari, Andrea Rosario ;
Bertini, Riccardo ;
Cavicchia, Michela Rita ;
Giorgini, Simona ;
Allegretti, Marcello .
PHARMACOLOGY & THERAPEUTICS, 2006, 112 (01) :139-149
[5]  
BOZIC CR, 1995, J IMMUNOL, V154, P6048
[6]   Mechanisms of disease - The many roles of chemokines and chemokine receptors in inflammation [J].
Charo, IF ;
Ransohoff, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :610-621
[7]   Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice [J].
Chow, F. Y. ;
Nikolic-Paterson, D. J. ;
Ma, F. Y. ;
Ozols, E. ;
Rollins, B. J. ;
Tesch, G. H. .
DIABETOLOGIA, 2007, 50 (02) :471-480
[8]   Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice [J].
Chow, FY ;
Nikolic-Paterson, DJ ;
Ozols, E ;
Atkins, RC ;
Rollin, BJ ;
Tesch, GH .
KIDNEY INTERNATIONAL, 2006, 69 (01) :73-80
[9]  
Ciesielski CJ, 2002, EUR J IMMUNOL, V32, P2037, DOI 10.1002/1521-4141(200207)32:7<2037::AID-IMMU2037>3.0.CO
[10]  
2-I